BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management

被引：49

作者：

Girolimetti, Giulia ^{[1
]}

Perrone, Anna Myriam ^{[2
]}

Santini, Donatella ^{[3
]}

Barbieri, Elena ^{[4
]}

Guerra, Flora ^{[5
]}

Ferrari, Simona ^{[6
]}

Zamagni, Claudio ^{[4
]}

De Iaco, Pierandrea ^{[2
]}

Gasparre, Giuseppe ^{[1
]}

Turchetti, Daniela ^{[1
,6
]}

机构：

[1] Univ Bologna, Policlin S Orsola Malpighi, Unita Genet Med, Dipartimento Sci Med & Chirurg, I-40138 Bologna, Italy

[2] AOU Bologna, Policlin Orsola Malpighi, SSD Oncol Ginecol, I-40138 Bologna, Italy

[3] AOU Bologna, Policlin S Orsola Malpighi, UO Anat Patol, I-40138 Bologna, Italy

[4] AOU Bologna, Policlin S Orsola Malpighi, SSD Oncol Med, I-40138 Bologna, Italy

[5] Univ Salento, Dipartimento Sci & Tecnol Biol Ambientali, I-73100 Lecce, Italy

[6] AOU Bologna, Policlin S Orsola Malpighi, UO Genet Med, I-40138 Bologna, Italy

来源：

BIOMED RESEARCH INTERNATIONAL | 2014年 / 2014卷

关键词：

REDUCING SALPINGO-OOPHORECTOMY; RIBOSE POLYMERASE INHIBITORS; GERMLINE MUTATIONS; BREAST-CANCER; CASE SERIES; DNA-REPAIR; PROPHYLACTIC OOPHORECTOMY; CLINICAL CHARACTERISTICS; LIPOSOMAL DOXORUBICIN; SPORADIC BREAST;

D O I：

10.1155/2014/787143

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients has been suggested as a prognostic and predictive factor. In addition, the identification of asymptomatic carriers of such mutations offers an unprecedented opportunity for OC prevention. This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated OC predisposition, on pathology and clinical behavior of OC occurring in BRCA mutation carriers, and on the available options for managing asymptomatic carriers.

引用

页数：11

共 120 条

[1] A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer [J].

Adams, Sarah F. ;

Marsh, Evelyn B. ;

Elmasri, Wafic ;

Halberstadt, Steffanie ;

VanDecker, Stephanie ;

Sammel, Mary D. ;

Bradbury, Angela R. ;

Daly, Mary ;

Karlan, Beth ;

Rubin, Stephen C. .

GYNECOLOGIC ONCOLOGY, 2011, 123 (03) :486-491

[2] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[3]

[Anonymous], NCCN CLIN PRACT GUID

[4]

[Anonymous], 2013, PLOS ONE, DOI DOI 10.1371/journal.pone.0058182

[5]

[Anonymous], 2012, Am Soc Clin Oncol, DOI DOI 10.1200/JCO.2012.30.15_SUPPL.5001

[6]

[Anonymous], OVARIAN CANC CLIN TR

[7] Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer [J].

Anton-Culver, H ;

Cohen, PF ;

Gildea, ME ;

Ziogas, A .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) :1200-1208

[8] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].

Antoniou, A ;

Pharoah, PDP ;

Narod, S ;

Risch, HA ;

Eyfjord, JE ;

Hopper, JL ;

Loman, N ;

Olsson, H ;

Johannsson, O ;

Borg, Å ;

Pasini, B ;

Radice, P ;

Manoukian, S ;

Eccles, DM ;

Tang, N ;

Olah, E ;

Anton-Culver, H ;

Warner, E ;

Lubinski, J ;

Gronwald, J ;

Gorski, B ;

Tulinius, H ;

Thorlacius, S ;

Eerola, H ;

Nevanlinna, H ;

Syrjäkoski, K ;

Kallioniemi, OP ;

Thompson, D ;

Evans, C ;

Peto, J ;

Lalloo, F ;

Evans, DG ;

Easton, DF .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130

[9] Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2 [J].

Arbini, A. A. ;

Guerra, F. ;

Greco, M. ;

Marra, E. ;

Gandee, L. ;

Xiao, G. ;

Lotan, Y. ;

Gasparre, G. ;

Hsieh, J-T ;

Moro, L. .

ONCOGENESIS, 2013, 2 :e82-e82

[10] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

← 1 2 3 4 5 6 7 8 9 10 →